Next Article in Journal
Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors
Next Article in Special Issue
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Previous Article in Journal
Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks
Previous Article in Special Issue
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(1), 28;

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma

Department of Medicine, University of Washington, Seattle, WA 98195, USA
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Author to whom correspondence should be addressed.
Academic Editor: Luciano J. Costa
Received: 27 January 2017 / Revised: 6 March 2017 / Accepted: 8 March 2017 / Published: 10 March 2017
(This article belongs to the Special Issue New Drugs in Hematology)
Full-Text   |   PDF [233 KB, uploaded 13 March 2017]


The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL. View Full-Text
Keywords: stem cell transplantation; mantle cell lymphoma; maintenance therapy stem cell transplantation; mantle cell lymphoma; maintenance therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Yan, F.; Gopal, A.K.; Graf, S.A. Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. Pharmaceuticals 2017, 10, 28.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top